Compare Stocks: AORT, LIVN, ITGR, and HAE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$26.26 -2.4%	$23.34	$19.16 ▼ $48.25	$1.31B	1.25	545,356 shs	964,006 shs
HAE Haemonetics	$83.80 -1.8%	$76.23	$47.31 ▼ $88.58	$3.88B	0.52	668,504 shs	1.14 million shs
ITGR Integer	$124.93 -0.1%	$95.99	$62.00 ▼ $125.54	$4.25B	0.61	1.31 million shs	1.89 million shs
LIVN LivaNova	$78.14 -8.4%	$79.54	$45.64 ▼ $85.76	$4.69B	0.86	605,780 shs	1.86 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	-2.52%	-4.57%	+6.13%	-25.78%	-18.22%
HAE Haemonetics	-1.84%	-2.13%	+11.69%	+53.94%	+10.11%
ITGR Integer	-0.01%	+25.36%	+33.81%	+42.46%	+16.09%
LIVN LivaNova	-8.42%	-4.04%	-7.01%	+10.16%	+83.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$26.26 -2.4%	$23.34	$19.16 ▼ $48.25	$1.31B	1.25	545,356 shs	964,006 shs
HAE Haemonetics	$83.80 -1.8%	$76.23	$47.31 ▼ $88.58	$3.88B	0.52	668,504 shs	1.14 million shs
ITGR Integer	$124.93 -0.1%	$95.99	$62.00 ▼ $125.54	$4.25B	0.61	1.31 million shs	1.89 million shs
LIVN LivaNova	$78.14 -8.4%	$79.54	$45.64 ▼ $85.76	$4.69B	0.86	605,780 shs	1.86 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	-2.52%	-4.57%	+6.13%	-25.78%	-18.22%
HAE Haemonetics	-1.84%	-2.13%	+11.69%	+53.94%	+10.11%
ITGR Integer	-0.01%	+25.36%	+33.81%	+42.46%	+16.09%
LIVN LivaNova	-8.42%	-4.04%	-7.01%	+10.16%	+83.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	2.75	Moderate Buy	$44.17	68.18% Upside
HAE Haemonetics	2.82	Moderate Buy	$78.89	-5.86% Downside
ITGR Integer	2.07	Hold	$109.86	-12.06% Downside
LIVN LivaNova	2.73	Moderate Buy	$83.50	6.86% Upside

Current Analyst Ratings Breakdown

Latest AORT, LIVN, ITGR, and HAE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	LIVN LivaNova	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$85.00
8/5/2026	LIVN LivaNova	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$81.00 ➝ $93.00
8/4/2026	LIVN LivaNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/4/2026	ITGR Integer	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/4/2026	ITGR Integer	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$84.00 ➝ $127.00
8/3/2026	ITGR Integer	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/3/2026	ITGR Integer	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$110.00 ➝ $127.00
8/3/2026	ITGR Integer	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
8/3/2026	ITGR Integer	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Hold	$127.00
8/3/2026	ITGR Integer	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Sector Weight
8/3/2026	ITGR Integer	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$441.33M	2.89	$1.08 per share	24.41	$9.46 per share	2.78
HAE Haemonetics	$1.33B	2.86	$7.44 per share	11.26	$17.14 per share	4.89
ITGR Integer	$1.85B	2.29	$10.36 per share	12.06	$49.85 per share	2.51
LIVN LivaNova	$1.43B	2.99	$4.43 per share	17.64	$21.98 per share	3.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	$9.77M	$0.24	109.43	35.02	N/A	2.55%	7.15%	3.63%	8/6/2026 (Estimated)
HAE Haemonetics	$97.31M	$2.02	41.49	14.65	1.72	7.29%	27.30%	9.59%	8/6/2026 (Estimated)
ITGR Integer	$102.81M	$4.01	34.13	18.48	2.98	6.97%	12.77%	6.48%	10/22/2026 (Estimated)
LIVN LivaNova	-$242.47M	$1.95	40.07	19.15	N/A	7.48%	16.48%	7.59%	N/A

Latest AORT, LIVN, ITGR, and HAE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AORT Artivion	$0.0025	N/A	N/A	N/A	$119.99 million	N/A
8/6/2026	Q1 2027	HAE Haemonetics	$1.08	N/A	N/A	N/A	$327.86 million	N/A
8/5/2026	Q2 2026	LIVN LivaNova	$1.08	$1.26	+$0.18	$1.93	$380.34 million	$390.59 million
8/3/2026	Q2 2026	ITGR Integer	$1.38	$1.60	+$0.22	$0.69	$451.07 million	$464.11 million
5/7/2026	Q4 2026	HAE Haemonetics	$1.28	$1.29	+$0.01	-$0.44	$336.83 million	$346.35 million
5/6/2026	Q1 2026	LIVN LivaNova	$0.85	$0.98	+$0.13	$0.40	$346.05 million	$362.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
ITGR Integer	N/A	N/A	N/A	N/A	N/A
LIVN LivaNova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.48	3.86	2.80
HAE Haemonetics	1.53	2.95	1.87
ITGR Integer	0.77	3.75	2.38
LIVN LivaNova	0.24	1.33	1.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
HAE Haemonetics	99.67%
ITGR Integer	99.29%
LIVN LivaNova	97.64%

Insider Ownership

Company	Insider Ownership
AORT Artivion	6.30%
HAE Haemonetics	2.07%
ITGR Integer	1.10%
LIVN LivaNova	0.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,800	48.54 million	45.49 million	Optionable
HAE Haemonetics	3,009	45.45 million	44.51 million	Optionable
ITGR Integer	11,000	33.96 million	33.58 million	Optionable
LIVN LivaNova	3,300	54.93 million	54.74 million	Optionable

AORT, LIVN, ITGR, and HAE Headlines

Recent News About These Companies

LivaNova (NASDAQ:LIVN) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

August 5 at 12:10 AM | marketbeat.com

LivaNova PLC 2026 Q2 - Results - Earnings Call Presentation

August 5 at 4:33 PM | seekingalpha.com

Needham & Company LLC Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

August 5 at 2:05 PM | marketbeat.com

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

August 5 at 2:00 PM | seekingalpha.com

LivaNova Q2 Earnings Call Highlights

August 5 at 1:03 PM | marketbeat.com

LivaNova (NASDAQ:LIVN) Shares Gap Down - Here's Why

August 5 at 12:59 PM | marketbeat.com

LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say

August 5 at 10:31 AM | zacks.com

LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?

August 5 at 10:16 AM | zacks.com

LivaNova: Q2 Earnings Snapshot

August 5 at 9:34 AM | finance.yahoo.com

LivaNova exceeds second-quarter forecasts and increases 2026 outlook

August 5 at 9:34 AM | msn.com

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

August 5 at 8:26 AM | zacks.com

LivaNova (NASDAQ:LIVN) Updates FY 2026 Earnings Guidance

August 5 at 7:40 AM | marketbeat.com

LivaNova (NASDAQ:LIVN) Hits New 1-Year High - Here's Why

August 4 at 6:19 PM | marketbeat.com

Janus Henderson Group PLC Purchases 448,703 Shares of LivaNova PLC $LIVN

August 3 at 5:19 AM | marketbeat.com

Renaissance Technologies LLC Has $11.63 Million Stock Position in LivaNova PLC $LIVN

August 2, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Sells 52,588 Shares of LivaNova PLC $LIVN

July 31, 2026 | marketbeat.com

Sei Investments Co. Acquires 79,088 Shares of LivaNova PLC $LIVN

July 31, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Makes New Investment in LivaNova PLC $LIVN

July 31, 2026 | marketbeat.com

LivaNova (LIVN) Expected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

Maverick Capital Ltd. Invests $956,000 in LivaNova PLC $LIVN

July 29, 2026 | marketbeat.com

Dimensional Fund Advisors LP Has $116.07 Million Holdings in LivaNova PLC $LIVN

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT, LIVN, ITGR, and HAE Company Descriptions

Artivion NYSE:AORT

$26.26 -0.64 (-2.37%)

Closing price 08/5/2026 03:59 PM Eastern

Extended Trading

$26.08 -0.18 (-0.69%)

As of 05:20 AM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Haemonetics NYSE:HAE

$83.80 -1.58 (-1.85%)

Closing price 08/5/2026 03:59 PM Eastern

Extended Trading

$81.00 -2.80 (-3.34%)

As of 05:48 AM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Integer NYSE:ITGR

$124.93 -0.12 (-0.10%)

Closing price 08/5/2026 03:59 PM Eastern

Extended Trading

$124.62 -0.31 (-0.25%)

As of 04:00 AM Eastern

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

LivaNova NASDAQ:LIVN

$78.14 -7.18 (-8.42%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$77.16 -0.98 (-1.25%)

As of 05:39 AM Eastern

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AORT, LIVN, ITGR, and HAE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AORT, LIVN, ITGR, and HAE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AORT, LIVN, ITGR, and HAE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT, LIVN, ITGR, and HAE Company Descriptions

Artivion NYSE:AORT

Haemonetics NYSE:HAE

Integer NYSE:ITGR

LivaNova NASDAQ:LIVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AORT, LIVN, ITGR, and HAE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AORT, LIVN, ITGR, and HAE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AORT, LIVN, ITGR, and HAE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT, LIVN, ITGR, and HAE Company Descriptions

Artivion NYSE:AORT

Haemonetics NYSE:HAE

Integer NYSE:ITGR

LivaNova NASDAQ:LIVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools